rxstat › Shortages › Bazedoxifene Conjugated Estrogens
Bazedoxifene Conjugated Estrogens (Duavive) shortage status
Shortage anticipated
A combination used to treat menopausal symptoms and help prevent osteoporosis.
Shortage history
Reports by product
What's happening
A manufacturer has told Health Canada it expects supply of Bazedoxifene Conjugated Estrogens to fall short of demand. Anticipated shortages sometimes resolve without patients noticing; this page updates as soon as the status changes.
Bazedoxifene Conjugated Estrogens is classified under “ESTROGENS” (ATC G03CC).
Recent changes
- Jul 29, 2026 New report filed
Common questions
What is Bazedoxifene Conjugated Estrogens used for?
A combination used to treat menopausal symptoms and help prevent osteoporosis.
When will Bazedoxifene Conjugated Estrogens be back in stock in Canada?
Manufacturers have not provided a reliable end date. This page updates automatically as soon as an estimate is filed.
Why is Bazedoxifene Conjugated Estrogens in shortage?
See the reports above; manufacturers must state a reason (most commonly manufacturing disruption or a surge in demand) when filing with Health Canada.
What can my pharmacist do about it?
Often quite a lot: substitute an equivalent product from an unaffected manufacturer, adjust quantities, or in most provinces adapt or renew prescriptions on the spot. Call your pharmacy before visiting, and call 811 for free health advice.
Email alerts
Possible alternatives in the same class (estrogens)
Data reflects reports manufacturers are legally required to file with Health Canada, republished with per-drug aggregation by rxstat. Estimated end dates are supplied by manufacturers and frequently change. This page describes drug supply only and is not medical advice; never stop or switch a medication without speaking to your pharmacist or prescriber.